Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(4 sites)

France

Institut Paoli Calmettes, Marseille

Centre hospitalier universitaire de Nantes, Nantes

Hôpital Saint-Louis, Paris

CHU Toulouse- Institut Universitaire du cancer Toulouse- Oncopole, Toulouse